X4 Pharmaceuticals, Inc.
A Boston-based biopharmaceutical company that makes medicines for rare immune-system diseases. Its drug XOLREMDI (mavorixafor), an oral pill approved by the FDA, treats WHIM syndrome, an ultra-rare inherited disorder that traps infection-fighting white blood cells in the bone marrow. Founded around 2015, the company took its name from the CXCR4 receptor its drug targets, and it built its lead medicine from a molecule originally developed by Sanofi.
Bought 500.0K
Granted 4.27M · Sold 928.7K
Bought 500.0K
Granted 1.30M · Sold 224.3K
Granted 875.8K · Sold 11.6K
Granted 1.65M · Sold 798.9K
Bought 500.0K
Bought 500.0K
Bought 500.0K
Bought 200.0K
Granted 566.3K · Sold 177.4K
Granted 289.9K · Bought 86.2K
Granted 289.9K
Bought 300.0K
Bought 300.0K
Granted 250.0K
Granted 193.3K · Sold 17.0K
Granted 202.7K · Sold 57.6K
Granted 105.0K · Sold 928
Bought 20.0K
Granted 96.7K
Granted 96.7K
Granted 17.5K · Sold 5.8K
Granted 745.7K · Bought 35.0K · Sold 50.5K
Granted 323.1K · Sold 130.1K
Granted 3.3K
Granted 136.5K
Granted 98.2K · Bought 25.0K
Granted 98.2K
Granted 98.2K
Granted 98.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Ross Michael JayDirector, 10% owner · 14 transactions | — | 5.15Mas of Nov 2017 | — | 500.0K | — |
| Ragan PaulaPresident and CEO, Director · 52 transactions | — | 3.34Mas of Feb 2025 | 4.27M | — | 928.7K |
| Gordon Carl LDirector, 10% owner · 6 transactions | — | 1.37Mas of Nov 2017 | — | 500.0K | — |
| DiBiase MaryChief Operating Officer · 23 transactions | — | 1.14Mas of Feb 2025 | 1.30M | — | 224.3K |
| Arbet-Engels ChristopheChief Medical Officer · 3 transactions | — | 864.2Kas of Feb 2025 | 875.8K | — | 11.6K |
| Mostafa Adam S.Chief Financial Officer · 33 transactions | — | 850.0Kas of Feb 2025 | 1.65M | — | 798.9K |
| Bill & Melinda Gates Foundation10% owner · 1 transaction | — | 722.2Kas of Nov 2017 | — | — | — |
| SV Life Sciences Fund V LP +4 co-filers10% owner · 14 transactions | — | 712.6Kas of Nov 2017 | — | 500.0K | — |
| Isaly Samuel D +2 co-filers10% owner · 6 transactions | — | 600.7Kas of Nov 2017 | — | — | — |
| Flint Jonathan A +5 co-filers10% owner · 24 transactions | — | 597.5Kas of Nov 2017 | — | 500.0K | — |
| McGuire TerranceDirector, 10% owner · 24 transactions | — | 589.1Kas of Nov 2017 | — | 500.0K | — |
| Alphabet Inc. +3 co-filers10% owner · 1 transaction | — | 451.4Kas of Nov 2017 | — | — | — |
| Maris William J +2 co-filers10% owner · 1 transaction | — | 451.4Kas of Nov 2017 | — | — | — |
| Gerngross Tillman U.Director · 2 transactions | — | 392.8Kas of Nov 2017 | — | 200.0K | — |
| Taveras ArthurChief Scientific Officer · 11 transactions | — | 388.0Kas of Oct 2024 | 566.3K | — | 177.4K |
| Craig Adam RExecutive Chairman, Director · 2 transactions | — | 376.1K | 289.9K | 86.2K | — |
| Volpone JohnPresident · 1 transaction | — | 289.9Kas of Aug 2025 | 289.9K | — | — |
| NeoMed Innovation V L.P. +2 co-filers10% owner · 4 transactions | — | 288.6Kas of Nov 2017 | — | 300.0K | — |
| Nessi ClaudioDirector · 4 transactions | — | 288.6Kas of Nov 2017 | — | 300.0K | — |
| Gray MichaelPresident, CEO and CFO, Director · 1 transaction | — | 250.0Kas of Nov 2018 | 250.0K | — | — |
| Alexandria Venture Investments, LLC10% owner · 1 transaction | — | 225.7Kas of Nov 2017 | — | — | — |
| Kirske DavidChief Financial Officer · 2 transactions | — | 176.3K | 193.3K | — | 17.0K |
| Meisner Derek MChief Legal Officer · 14 transactions | — | 145.2Kas of Aug 2022 | 202.7K | — | 57.6K |
| Cadavid DiegoChief Medical Officer · 3 transactions | — | 104.1Kas of Mar 2022 | 105.0K | — | 928 |
| Adams Jan +4 co-filers10% owner · 3 transactions | — | 103.3Kas of Nov 2017 | — | 20.0K | — |
| Aliski WilliamDirector · 3 transactions | — | 96.7Kas of Jun 2024 | 96.7K | — | — |
| Lawton Alison FrancesDirector · 3 transactions | — | 96.7Kas of Jun 2024 | 96.7K | — | — |
| Skerlj RenatoChief Scientific Officer · 3 transactions | — | 42.1Kas of Sep 2020 | 17.5K | — | 5.8K |
| Anna-Maria & Stephen Kellen Foundation, Inc.10% owner · 2 transactions | — | 25.8Kas of Nov 2017 | — | — | — |
| Baldry MarkChief Commercial Officer · 10 transactions | — | 25.3Kas of May 2025 | 745.7K | 35.0K | 50.5K |
| Stewart MurrayDirector · 5 transactions | — | 7.9Kas of Jun 2025 | 323.1K | — | 130.1K |
| Thoren Natasha FayChief Legal Officer · 1 transaction | — | 7.0Kas of Jun 2025 | 3.3K | — | — |
| Woods KeithDirector · 3 transactions | — | 6.0Kas of Jun 2025 | 136.5K | — | — |
| Wyzga Michael SDirector · 5 transactions | — | 5.6Kas of Jun 2025 | 98.2K | 25.0K | — |
| Bridger GaryDirector · 4 transactions | — | 4.7Kas of Jun 2025 | 98.2K | — | — |
| McGirr David W JDirector · 4 transactions | — | 4.7Kas of Jun 2025 | 98.2K | — | — |
| de Craecker FrancoiseDirector · 4 transactions | — | 4.7Kas of Jun 2025 | 98.2K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +1.06M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.